萬華化學(600309.SH)仍計劃在美國擁有40萬噸MDI產品生產能力
格隆匯11月1日丨萬華化學(600309.SH)公佈,公司於2018年11月17日披露了“關於在美國建設MDI一體化項目的公告”,在開展初步設計過程中,由於外部環境快速變化,項目投資成本大幅增加,公司正在重新評估美國項目的建設範圍和選址。雖然美國MDI項目遇到了一些困難和挑戰,但公司仍計劃在美國擁有40萬噸MDI產品生產能力。
美國項目投產前,公司仍將繼續通過現有中國、歐洲等地產品貨源,服務北美市場,保證客户穩定供應。
美國項目的調整不會對公司財務狀況產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.